Elisabeth Sandoval-Little

Elisabeth Sandoval-Little was appointed to their Board of Directors in April 2021. Ms. Sandoval-Little currently serves as a consultant to the pharmaceutical industry. From September 2016 to April 2019, Ms. Sandoval-Little served as the Chief Commercial Officer and Executive Vice President of Corporate Strategy of Alder Biopharmaceuticals, a public biopharmaceutical company. Before joining Alder, Ms. Sandoval-Little was Chief Commercial Officer for Kythera Biopharmaceuticals, a publicly traded biopharmaceutical company, acquired by Allergan in 2015, from March 2012 to October 2015. Ms. Sandoval-Little currently serves on the board of directors of Satsuma Pharmaceuticals, Inc., a public pharmaceutical company. Ms. Sandoval-Little also currently serves on the board of directors of VYNE Therapeutics, a public pharmaceutical company, as well as on the board of directors of one private company. Ms. Sandoval-Little holds an M.B.A. from Pepperdine University and a B.S. in Biology from the University of California, Irvine.